Pregabalin Capsule
Product Images NDC 60760-768

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-768). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregab (Pregabalin 60760 768 60)

Label for Pregabalin Capsules 50 mg, quantity 60, with NDC 60760-768-60. The label shows the drug name, strength, dosage form, quantity, manufacturer details (Hetero Labs Limited, India), and packaging information by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. It also includes barcode and storage instructions at controlled room temperature (15°-30°C).*

FDA Label Image

Camberlogo (Camberlogo)

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares the effects of Pregabalin at 25 mg, 100 mg, and 200 mg taken three times a day, as well as a placebo, with Pregabalin 200 mg three times a day showing the highest percent of patients improved across increasing levels of improvement in pain.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over a period of 180 days between Pregabalin and placebo groups. The Y-axis shows the estimated percent of subjects without LTR, while the X-axis shows time in days. The Pregabalin group has a higher percentage of subjects without LTR across the timeframe compared to placebo.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved from baseline to Week 12 BOCF for Pregabalin versus Placebo. The y-axis represents the percent of subjects improved, ranging from 0 to 100%, and the x-axis shows the percent improved from baseline to Week 12 BOCF, ranging from greater than 0 to 100. Pregabalin shows a higher improvement percentage across the range compared to Placebo.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing the percent of subjects improved over time between Pregabalin and Placebo groups. The x-axis represents percent improved from baseline to week 16 BOCF, and the y-axis shows the percent of subjects improved, with two curves illustrating the difference in outcomes between Pregabalin and Placebo.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph displaying the percent of patients improved plotted against percent improvement in pain from baseline. Two lines are shown: one for Pregabalin 100 mg three times a day and one for placebo, illustrating different pain improvement outcomes over a range of percentages.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares multiple treatment groups including Pregabalin at 75 mg, 150 mg, and 300 mg taken two times a day, and a placebo group, showing differences in pain improvement outcomes.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph illustrating the percent of patients improved relative to the percent improvement in pain from baseline. It compares three groups: patients taking Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo group. The vertical axis shows percent of patients improved; the horizontal axis shows percent improvement in pain.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph showing the percentage of patients improved based on the percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups, with percent improvement on the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar graph titled 'Study E1' and 'Study E3' displays responder rates (%) for Pregabalin at various dosages compared to placebo. The x-axis shows dosage groups including placebo, 150 mg/day, 300 mg/day, and 600 mg/day with different administration schedules, while the y-axis shows responder rates from 0% to 60%. Bars indicate increasing responder rates with higher Pregabalin doses in both studies.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A dose-response line chart showing median seizure reduction percentages from baseline versus daily dose (mg/day) for Pregabalin at different dosing frequencies (BID and TID). Four study groups (Study E1 BID, Study E2 TID, Study E3 BID, Study E3 TID) are plotted with distinct markers, each indicating statistically significant seizure reduction at increasing doses compared to placebo.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A vertical bar chart showing responder rates (%) for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The responder rates are approximately 22.6%, 29.1%, and 40.6%, respectively, with sample sizes of 93, 103, and 96 shown below each bar. The y-axis is labeled 'Responder Rate (%)' and ranges from 0 to 60.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline for Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo. The graph compares these four groups over a range of pain improvement percentages from 0 to 100 percent.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure diagram of Pregabalin, showing its molecular configuration with labeled atoms and bonding.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.